SavedAdd your journal

Journals / Güncel Retina Dergisi / 2019 / Cilt: 3 - Sayı: 2

Incomplete Treatment Response, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Branch Retinal Vein Occlusion and Macular Edema

Retina Ven Dal Tıkanıklığı ve Maküla Ödeminde Tedaviye Yanıtsızlık, Tedaviye Direnç, İlaç Değişimleri ve Kombine Tedaviler

Burcu NURÖZLER TABAKCI
NURTEN ÜNLÜ
Pages
108–111
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, incomplete treatment response, treatment resistance, pharmaceutical changes and combined treatment are mentioned in cases with BRVO and macular edema.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Branch retinal vein occlusion (BRVO) is the second most common retinal vascular disease after diabetic retinopathy.
📊
Key Findings & Data:Anti- VEGF agents are preferred in the treatment of macular edema due to BRVO because of the increase in visual acuity.
💡
Conclusion & Impact:In this review, incomplete treatment response, treatment resistance, pharmaceutical changes and combined treatment are mentioned in cases with BRVO and macular edema.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Branch retinal vein occlusion (BRVO) is the second most common retinal vascular disease after diabetic retinopathy. Vision loss varies depending on the affected area. The main causes of vision loss in BRVO are macular edema and macular ischemia. Anti- VEGF agents are preferred in the treatment of macular edema due to BRVO because of the increase in visual acuity. Although anti-VEGF therapy provides early response, in some cases macular edema is resistant to the treatment. In this review, incomplete treatment response, treatment resistance, pharmaceutical changes and combined treatment are mentioned in cases with BRVO and macular edema.

Özet

Retinal ven dal tıkanıklığı (RVDT) diyabetik retinopatiden sonra en sık görülen retina damar hastalığıdır. Görme kaybı etkilenen venin bulunduğu bölgeye göre değişkendir. RVDT’nda görme kaybının başlıca nedenleri maküla ödemi ve maküler iskemidir. Anti-VEGF ajanlar, RVDT’na bağlı makula ödeminde görme keskinliğinde artış sağlaması nedeniyle tedavide öncelikli tercih edilmektedir. Anti-VEGF tedavi ile erken yanıt alınsa da bazı olgularda maküla ödemi tedaviye dirençlidir. Bu derlemede RVDT ve maküla ödeminde tedaviye yanıtsızlık, tedaviye direnç, ilaç değişimleri ve kombine tedaviler gözden geçirilecektir.

🔖

Cite This Article

TABAKCI, B. N., ÜNLÜ, N. (2019). Incomplete Treatment Response, Treatment Resistance, Pharmaceutical Changes and Combined Treatments in Branch Retinal Vein Occlusion and Macular Edema. Güncel Retina Dergisi, Cilt: 3 - Sayı: 2, 108–111. https://ajindex.com/articles/165019

References (12)

  1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141
  2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res. 2008;33(2):111–131
  3. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313–319
  4. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina. 2013;33(5):901–910
  5. Rogers SL, McIntosh RL, Lim L, Mitchell P, Cheung N, Kowalski JW, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094–1101
  6. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98(3):271- 282
  7. Hayreh SS, Zimmerman MB. Branch retinal vein occlusion: natural history of visual outcome. JAMA Ophthalmol. 2014;132(1):13-22
  8. The Score Study Research Group.: A randomized trial comparing the efficiacy and safety of intravitreal triamcinolone with standart care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion (The standart care vs corticosteroid for retinal vein occlusion (SCORE) study report 6). Arch Ophthalmol. 2009;127(9):1115-1128
  9. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1102-1112
  10. Tadayoni R, Waldstein SM, Boscia F, Gerding H, Pearce I, Priglinger S, et al. BRIGHTER study group. Individualized stabilization criteria-driven ranibizumab versus laser in branch retinal vein occlusion: six-month results of BRIGHTER. Ophthalmology. 2016;123(6):1332-1344
  11. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. RETAIN Study Group. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab:the RETAIN study. Ophthalmology. 2014;121(1):209–219
  12. Hanada N, Iijima H, Sakurada Y, Imasawa M. Recurrence of macular edema associated with branch retinal vein occl